H G Lyu1, L V Saadat1, M M Bertagnolli1,2, J Wang1,2, E H Baldini3,2,4, M Stopfkuchen-Evans5, R Bleday1,4, C P Raut1,3. 1. Departments of Surgery, Boston, Massachusetts, USA. 2. Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. 3. Radiation Oncology, Boston, Massachusetts, USA. 4. Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA. 5. Anesthesiology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Abstract
BACKGROUND: Patients undergoing surgery for soft tissue sarcoma have high morbidity rates, particularly after preoperative radiation therapy (RT). An enhanced recovery after surgery (ERAS) programme may improve perioperative outcomes in abdominal surgery. This study reported outcomes of an ERAS programme tailored to patients with soft tissue sarcoma. METHODS: A prospective ERAS protocol was implemented in 2015 at a high-volume sarcoma centre. Patients treated within the ERAS programme from 2015 to 2018 were case-matched retrospectively with patients treated between 2012 and 2018 without use of the protocol, matched by surgical site, surgeon, sarcoma histology and preoperative RT treatment. Postoperative outcomes, specifically wound complications and duration of hospital stay, were reported. RESULTS: In total, 234 patients treated within the ERAS programme were matched with 237 who were not. The ERAS group had lower wound dehiscence rates overall (2 of 234 (0·9 per cent) versus 31 of 237 (13·1 per cent); P < 0·001), after preoperative RT (0 of 41 versus 11 of 51; P = 0·004) and after extremity sarcoma surgery (0 of 54 versus 6 of 56; P = 0·040) compared with the non-ERAS group. Rates of postoperative ileus or obstruction were lower in the ERAS group (21 of 234 (9·9 per cent) versus 40 of 237 (16·9 per cent); P = 0·016) and in those with retroperitoneal sarcoma (4 of 36 versus 15 of 36; P = 0·007). Duration of hospital stay was shorter in the ERAS group (median 5 (range 0-36) versus 6 (0-67) days; P = 0·003). CONCLUSION: Treatment within an ERAS protocol for patients with soft tissue sarcoma was associated with lower morbidity and shorter hospital stay.
BACKGROUND:Patients undergoing surgery for soft tissue sarcoma have high morbidity rates, particularly after preoperative radiation therapy (RT). An enhanced recovery after surgery (ERAS) programme may improve perioperative outcomes in abdominal surgery. This study reported outcomes of an ERAS programme tailored to patients with soft tissue sarcoma. METHODS: A prospective ERAS protocol was implemented in 2015 at a high-volume sarcoma centre. Patients treated within the ERAS programme from 2015 to 2018 were case-matched retrospectively with patients treated between 2012 and 2018 without use of the protocol, matched by surgical site, surgeon, sarcoma histology and preoperative RT treatment. Postoperative outcomes, specifically wound complications and duration of hospital stay, were reported. RESULTS: In total, 234 patients treated within the ERAS programme were matched with 237 who were not. The ERAS group had lower wound dehiscence rates overall (2 of 234 (0·9 per cent) versus 31 of 237 (13·1 per cent); P < 0·001), after preoperative RT (0 of 41 versus 11 of 51; P = 0·004) and after extremity sarcoma surgery (0 of 54 versus 6 of 56; P = 0·040) compared with the non-ERAS group. Rates of postoperative ileus or obstruction were lower in the ERAS group (21 of 234 (9·9 per cent) versus 40 of 237 (16·9 per cent); P = 0·016) and in those with retroperitoneal sarcoma (4 of 36 versus 15 of 36; P = 0·007). Duration of hospital stay was shorter in the ERAS group (median 5 (range 0-36) versus 6 (0-67) days; P = 0·003). CONCLUSION: Treatment within an ERAS protocol for patients with soft tissue sarcoma was associated with lower morbidity and shorter hospital stay.
Authors: Massimiliano Greco; Giovanni Capretti; Luigi Beretta; Marco Gemma; Nicolò Pecorelli; Marco Braga Journal: World J Surg Date: 2014-06 Impact factor: 3.352
Authors: Aileen M Davis; Brian O'Sullivan; Robert Turcotte; Robert Bell; Charles Catton; Pierre Chabot; Jay Wunder; Alex Hammond; Veronique Benk; Rita Kandel; Karen Goddard; Carolyn Freeman; Anna Sadura; Benny Zee; Andrew Day; Dongsheng Tu; Joseph Pater Journal: Radiother Oncol Date: 2005-04 Impact factor: 6.280
Authors: Elizabeth H Baldini; Michelle R Lapidus; Qian Wang; Judith Manola; Dennis P Orgill; Bohdan Pomahac; Karen J Marcus; Monica M Bertagnolli; Phillip M Devlin; Suzanne George; John Abraham; Marco L Ferrone; John E Ready; Chandrajit P Raut Journal: Ann Surg Oncol Date: 2012-12-15 Impact factor: 5.344
Authors: Brian O'Sullivan; Aileen M Davis; Robert Turcotte; Robert Bell; Charles Catton; Pierre Chabot; Jay Wunder; Rita Kandel; Karen Goddard; Anna Sadura; Joseph Pater; Benny Zee Journal: Lancet Date: 2002-06-29 Impact factor: 79.321
Authors: A J Mundt; A Awan; G S Sibley; M Simon; S J Rubin; B Samuels; W Wong; M Beckett; S Vijayakumar; R R Weichselbaum Journal: Int J Radiat Oncol Biol Phys Date: 1995-07-15 Impact factor: 7.038
Authors: Fabio Tirotta; Michael G Fadel; James Hodson; Alessandro Parente; Helene Wilkerson; L Max Almond; Samuel J Ford; Andrew J Hayes; Anant Desai; Dirk C Strauss Journal: Ann Surg Oncol Date: 2022-07-19 Impact factor: 4.339
Authors: Carol J Swallow; Dirk C Strauss; Sylvie Bonvalot; Piotr Rutkowski; Anant Desai; Rebecca A Gladdy; Ricardo Gonzalez; David E Gyorki; Mark Fairweather; Winan J van Houdt; Eberhard Stoeckle; Jae Berm Park; Markus Albertsmeier; Carolyn Nessim; Kenneth Cardona; Marco Fiore; Andrew Hayes; Dimitri Tzanis; Jacek Skoczylas; Samuel J Ford; Deanna Ng; John E Mullinax; Hayden Snow; Rick L Haas; Dario Callegaro; Myles J Smith; Toufik Bouhadiba; Silvia Stacchiotti; Robin L Jones; Thomas DeLaney; Christina L Roland; Chandrajit P Raut; Alessandro Gronchi Journal: Ann Surg Oncol Date: 2021-04-14 Impact factor: 4.339